Pulse Biosciences, Inc. Announces First Patient Enrollment in NANOPULSE-AF IDE Pivotal Clinical Study

Key Highlights

• First Patients Enrolled: Pulse Biosciences, Inc. has officially enrolled the first patients in its pivotal clinical study, NANOPULSE-AF IDE, evaluating the nPulse™ Cardiac Catheter System for the treatment of atrial fibrillation.
• Pivotal Clinical Study: The NANOPULSE-AF IDE study represents a critical step towards FDA approval and potential market entry for Pulse Biosciences’ flagship cardiac ablation technology.
• Innovative Technology: The nPulse™ Cardiac Catheter System utilizes the company’s proprietary non-thermal irreversible electroporation (nsPFA) technology, aiming to provide a disruptive and potentially superior treatment option for atrial fibrillation.
• Press Release Issued: The company disseminated a press release on April 7, 2026, to announce this milestone development.

Details for Investors

Pulse Biosciences, Inc. (Nasdaq: PLSE), based in Hayward, California and incorporated in Delaware, is a medical device company that develops and commercializes novel, proprietary therapies based on its Nano-Pulse Stimulation™ (NPS™) technology platform. The company’s latest development, the nPulse™ Cardiac Catheter System, is being evaluated in a pivotal clinical trial (NANOPULSE-AF IDE) for the treatment of atrial fibrillation (AF), a common and potentially serious cardiac arrhythmia.

The company’s nPulse™ System employs nsPFA (non-thermal irreversible electroporation), which aims to non-thermally ablate targeted cardiac tissue while sparing surrounding non-cellular structures. If successful, this technology could represent a significant advancement over conventional thermal ablation approaches that are currently the standard of care for atrial fibrillation.

The pivotal trial is designed to gather the necessary clinical evidence to support regulatory submissions and, ultimately, commercial launch. Early clinical successes have been referenced, but the company notes in its forward-looking statements that these may not necessarily predict the ultimate safety and effectiveness of the device.

Shareholder Relevance and Price Sensitivity:
The enrollment of the first patients in a pivotal study is a material event for a medical device company at Pulse Biosciences’ stage. The successful completion of pivotal studies is a key gate for FDA approval and commercial launch. The company’s forward-looking statements highlight expectations for the study, potential market opportunities, and the hope that their approach will become a disruptive or superior therapy for AF and possibly other medical conditions.

Any positive clinical data, regulatory milestones, or indications of safety and efficacy could be highly price sensitive for PLSE stockholders. Conversely, delays, negative outcomes, or safety concerns could negatively impact the share price. Investors should closely monitor updates from the NANOPULSE-AF IDE study, as these will directly affect the company’s valuation and future prospects.

Other Key Information

• Company Headquarters: 3957 Point Eden Way, Hayward, CA 94545 (current business address listed in filings; some filings list a Miami, FL address as well).
• CEO: Paul A. LaViolette signed the report as Chief Executive Officer.
• Trading Information: Pulse Biosciences’ common stock trades on the Nasdaq Stock Market under the symbol PLSE.
• Forward-Looking Statements: The press release and filing contain forward-looking statements regarding the expected impact of the company’s technology, market opportunities, and the clinical study. Actual results may differ materially due to risks and uncertainties.

Contact Information

Media:
Maggie Turano, Account Director at ICR Healthcare
[email protected]

Investors:
Jon Skinner, CFO, Pulse Biosciences, Inc.
[email protected]

Or
Philip Trip Taylor, Gilmartin Group
415.937.5406
[email protected]

Disclaimer

This article contains forward-looking statements based on current expectations, estimates, and projections of Pulse Biosciences, Inc. Actual results may differ materially from those discussed herein due to risks and uncertainties including, but not limited to, clinical study results, regulatory outcomes, and competitive developments. Investors should not place undue reliance on these statements and are encouraged to read the company’s filings with the Securities and Exchange Commission for a full understanding of potential risks. This article does not constitute an offer to buy or sell securities.

View PULSE BIOSCIENCES, INC. Historical chart here